Prolia Every Six Months: Appointments, Blood Tests and Treatment Reviews

Published May 26, 2026Updated Oct 15, 2026Last reviewed May 26, 2026

9 linked public sourcesEditorial, sourcing, and corrections policy

Prolia is a 60 mg healthcare-provider injection every six calendar months. Prolia and Xgeva contain denosumab but use different schedules and are not used together. Six months is not a fixed 182-day interval. [1]

Keep appointments connected to treatment reviews

Before leaving each appointment, record the actual injection date and arrange the next visit. Add reminders early enough to resolve insurance authorization, travel, transport or clinic availability. Keep the appointment details somewhere both you and anyone helping with your care can find them.

Timely appointments matter because denosumab’s protective effect reverses after treatment stops. The Endocrine Society advises against delaying or stopping it without subsequent treatment to limit rebound bone turnover, bone loss and fracture risk. A planned treatment review should therefore happen before a decision to interrupt injections. [2]

If your injection is already late, contact the prescribing team rather than waiting for a routine review. The late-dose guide covers that separate situation.

Blood tests depend on your risk

Selected patients predisposed to hypocalcemia need calcium and mineral checks 10–14 days afterward. Advanced CKD requires calcium checks weekly for the first month, then monthly. Your team sets the appropriate testing plan. [1]

The FDA’s boxed warning emphasizes severe hypocalcemia in advanced kidney disease, especially dialysis and chronic kidney disease–mineral and bone disorder. Existing low calcium needs correction before treatment. Treatment selection, calcium and vitamin D management, and monitoring require an experienced clinical team. Lack of a renal dose adjustment does not make treatment low-risk in this group. [3]

Ask which tests your clinician wants, when they should be completed, and who will review the results before the appointment. Do not assume that an old laboratory result or a supplement plan from another person is suitable for your next visit.

Your ongoing-care appointment worksheet

Use one copy for each injection cycle. This separates your records from tests or treatment changes that require a clinician’s decision.

Stage	Records to bring or complete	Questions for the care team
Before the visit	Last actual injection date; appointment details; updated medicine and supplement list; new symptoms, fractures or dental plans	Which blood tests are ordered? When and where should they be done? Who checks the results?
At the visit	Actual injection date; administering clinic; any tests reviewed; agreed follow-up instructions	Has my fracture risk or kidney health changed? Is the current treatment still appropriate?
After the visit	Next appointment; reminders; contact number; dates of any ordered follow-up tests	Who should I contact about symptoms, abnormal results or scheduling problems?

Leave space beneath the worksheet for unresolved questions. If an appointment changes, update both your calendar and the clinic’s record rather than relying on an earlier booking confirmation.

What the main studies establish

These studies answer different questions. Bone mineral density (BMD) improvement is useful evidence, but it is not the same endpoint as preventing fractures.

Study	Design and participants	Main finding and limitation
FREEDOM	Three-year placebo-controlled trial; 7,868 postmenopausal women	New radiographic vertebral fractures occurred in 2.3% with denosumab versus 7.2% with placebo—a 68% relative reduction. [5]
FREEDOM extension	Open-label extension; 4,550 entered and 2,626 completed	Exposure reached ten years in the long-term group. BMD continued increasing; there was no continuing randomized placebo group. Annual new vertebral fracture incidence ranged from 0.90% to 1.86%. [6]
Men’s trial	One-year placebo-controlled study; 242 randomized men	The primary endpoint was lumbar-spine BMD, which increased 5.7% with denosumab. It was not a fracture-prevention endpoint. [7]

Make room for broader treatment decisions

Prolia is approved for certain adults with glucocorticoid-induced osteoporosis. [1]

For people taking glucocorticoids long term, fracture-risk assessment remains important. The American College of Rheumatology guideline includes denosumab among treatment options chosen through shared decision-making; it is not restricted simply to people unable to tolerate oral bisphosphonates. [8]

Keep your dentist informed about osteoporosis medicines. The ADA emphasizes oral health and individualized planning: evidence does not support a routine antiresorptive holiday or waiting period to prevent medication-related jaw osteonecrosis. Dental work should prompt coordination, not an automatic cancelled injection. [4]

Frequently asked questions

What happens if I miss my denosumab injection by a few weeks?

Contact the clinic promptly. A missed dose is given as soon as available; the next interval starts six months from the actual injection. [1]

Can I switch from denosumab to a bisphosphonate?

Ask your osteoporosis prescriber to plan subsequent treatment. The guideline does not assign one bridge regimen to everyone. [2]

Do I need blood work before every denosumab injection?

Your care team orders tests according to your health and treatment. Ask which results need review before your visit. [9]

How long can I stay on denosumab?

Guidelines recommend fracture-risk reassessment after five to ten years. The extension followed selected patients for ten years. [2][6]

What is the correct vitamin D level before a denosumab injection?

Ask your clinician which vitamin D target and replacement plan fit your results. The Prolia label does not set a universal 30 ng/mL threshold. [1]

Is denosumab safe for patients with kidney disease?

Safety depends on kidney disease severity and mineral metabolism. Advanced CKD, particularly dialysis, substantially increases severe hypocalcemia risk and requires specialist-directed selection and monitoring—not reassurance based only on unchanged dosing. [3]

What is a bisphosphonate holiday and how does it relate to denosumab?

Selected bisphosphonate users may have a planned pause. Denosumab interruption requires subsequent treatment planning. [2]

Does denosumab work better than alendronate for osteoporosis?

The studies summarized here do not establish superiority over alendronate. FREEDOM compared denosumab with placebo, so its fracture results cannot answer that head-to-head question. [5]

Can men take denosumab on the same schedule?

Yes. The men’s study used 60 mg every six months. Its main evidence concerned BMD improvement over one year, rather than a demonstrated reduction in fractures. [7]

What are the signs of rebound bone loss after stopping denosumab?

Rebound bone loss and spinal fractures can occur after treatment stops. Report new or severe back pain rather than waiting for the next injection. [9]

Should I see a dentist before starting denosumab?

The prescriber should examine your mouth before treatment. A dental exam is recommended for people with risk factors for jaw osteonecrosis. Tell the dentist about Prolia and coordinate planned procedures with both clinicians. [1][4]

How is denosumab injected and where on the body?

A healthcare provider gives Prolia under the skin of the upper arm, upper thigh or abdomen. [9]